Voyager Reports Third Quarter 2025 Financial and Operating Results

Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on ...
Morning Overview on MSN

Voyager finds a blazing wall at the solar system’s edge

Decades after its launch, NASA’s Voyager spacecraft has made a startling discovery at the edge of our solar system. The probe ...

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia

CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company ...
The Globe and Mail

Voyager Provides Update on SOD1 ALS Gene Therapy Program

- All other programs remain on track; IND filings expected in 2025 for GBA1 and FA programs - LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a ...
ksn.com

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research

- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human primates (NHPs) - - Data to ...

Voyager Flat on Q3 Results

Voyager Therapeutics, Inc. (NASDAQ: VYGR) began Monday virtually unchanged The Lexington, Mass.- concern, a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today ...
The Globe and Mail

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s ...
Newswire

Voyager Digital Announces Expansion of Crypto Interest Program

Announces New Increased Interest Rates for USDC, Bitcoin and Ethereum - Adds Chainlink (LINK), Basic Attention Token, and Kyber Network to Voyager Interest Program, Offering Customers and Partners ...
Mena FN

Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program To Pipeline, Complementing Existing Tau And Amyloid Assets With New APOE Approach

(MENAFN- GlobeNewsWire - Nasdaq) - New program combines IV-delivered TRACERTM capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the ...